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INTRODUCTION
History of the stomach colonization by Helicobacter 
pylori 
Trillions of bacteria, collectively referred to as the microbiota, 
reside in the gastrointestinal tract, Helicobacter (Campylo-
bacter) pylori (H. pylori) being a member of this microbial 
society. In 1983 and 1984 Lancet published the first papers
of two Australian physicians, Marshall and Warren (1,2), 
demonstrating H. pylori infection in biopsy specimens from 
patients with gastritis. In paper published in 1985, Marshall 
and colleagues (3) reported a personal experiment using 
oral administration of H. pylori suspension by Dr Marshall 
himself, resulted in the development of gastritis shortly after 
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infection (see also 4). In fact, the presence of spirochete-like 
bacteria in the stomach has been recognized since 1892 (see 
5) (Table 1).  
Here we Dance Round possible role of gastrokines in 
metabolic pathways and food intake as related to cardi-
ometabolic diseases associated with H. pylori infection or 
its eradication.
H. PYLORI INFECTION AND GASTOKINES
Biology of H. pylori 
H. pylori is a curved or spiral shaped Gram negative, mobile 
bacterium. It measures 3-5 µm in length and approximately 0.5 
µm in diameter. H. pylori colonizes the stomachs of roughly 
half of the world's population and usually persists in the gas-
tric mucosa of human hosts for decades or life. Family unit 
is generally accepted as one of the contributors to H. pylori 
infection that is most frequently acquired in childhood. Al-
though most H. pylori-positive people are asymptomatic, the 
presence of H. pylori is associated with increased risk for the 
development of peptic ulcer disease, gastric adenocarcinoma 
and gastric lymphoma (reviewed in 5). The development of 
a sustained gastric inflammatory and immune response to H. 
pylori infection appears to play a pivotal role for the devel-
opment of these diseases. During its long co-existence with 
humans, H. pylori has evolved complex strategies to maintain 
a low-grade inflammation of the gastric epithelium. Important
local factors implicated in the pathobiology of H. pylori include 
urease-dependent NH3 production and the bacterial cytotoxin 
associated gene A (CagA). 
Gastrokines: what in the name?
Today, the number of “-kine” bioactive molecules as well 
as “-omics” sciences is dramatically increased. Generally 
referred to as cytokines and chemokines (Table 2), various 
molecules, depending on the cellular source of their secretion 
(synthesis, store, and release), were more specifically dubbed
adipokines (6-10), myokines (11,12) or enterokines (13). Here 
we introduce the term “gastrokines” to connote the bioactive 
molecules secreted by selected gastric cells, using both para- 
and endocrine pathway (Table 3). 
The host’s immune-inflammatory response, involving
paracrine overproduction of pro-inflammatory cytokines such
Table 1. History of the discovery of Helicobacter pylori
1892 –  Bizzozero: snake-line bodies in a dog stomach
1906 –  Krienitz: spirochete-like bodies in human stomach
1919 –  Kasai and Kobayashi: animal model for H. pylori infection and first H. pylori eradication 
1936 –  Doenges: isolation of from a human stomach
1954  –  Palmer: completely disproved the presence of bacteria in stomach; the gastric lumen was believed to be aseptic  
 about 30 years thereafter 
1982 – Warren and Marshal: detection and isolation form human stomach biopsy
1984 –  Recommendation of eradication therapy for all patients with peptic ulcers
1994 –  WHO: recognition as a carcinogen involved in the etiopatogenesis of gastric cancer 
1997 –  Tomb: total genome analysis 
2002 –  Marshal awarded the Keio Medical Prize
2005 –  Warren and Marshall awarded the Nobel prize in physiology or medicine 
Modified from Suzuki et al (5). Note the gap between the years of 1954 and 1982, when the scientific progress in the field is
blocked, a known phenomenon in science. 
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Table 2. A selected list of anti- and pro-inflammatory signals
Anti-inflammatory signals Pro-inflammatory signals
Adiponectin Tumor necrosis factor-α
Interleukin-10  Interleukin-1, -6, -18
Interleukin-1 receptor antagonist Leptin
Nerve growth factor  FIZZ-1*, Resistin (FIZZ-3)




Modified from Chaldakov et al (6). Note that all the listed mediators may also be secreted by adipose tissue cells (6-10,34-41). 
* FIZZ, found in inflammatory zone – a member of FIZZ family of secreted proteins
** Monocyte chemoattractant protein-1 (cysteine cysteine modif chemokine ligand)
*** RANTES, regulated on activated normal T-cell expressed and secreted





IL-1, IL-6, IL-8, TNF-α
Neurotrophins (NGF, BDNF, NT-3,-4/5,-6)
Enterokines*
Cholecystokinins
Peptide tyrosine tyrosine (PYY)
Orexin A and B
Incretins
  - glucagon-like protein-1
  - glucose-dependent insulinotropic protein
*  As indicated (36-43,45,46)
** In agreement with “-kines” terminology, cholecystokinins, PYY, and orexins (30) and incretins (44), secretory products of 
specific populations of gut endocrine cells, may be classified as enterokines (13); their likely links to the metabology of H. pylori 
infection remain to be examined
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as interleukin-1 (IL-1), IL-6, tumor necrosis factor-alpha 
(TNF-α) and the chemokine IL-8 (CXCL8), is accompanied 
by the enhanced epithelial cell proliferation; these events be-
ing involved in the processes of gastric mucosal alterations, 
including cancerogenesis (5). Additionally, an H. pylori-
induced chronic low-grade inflammation is involved in the 
pathogenesis of autoimmune diseases (14-16) and also cardi-
ometabolic diseases such as atherosclerosis, obesity, diabetes, 
and metabolic syndrome (17-23). 
The discovery of adipokines (6-10) and gastrointestinal cell-
secreted factors  (24-30) promotes investigations of possible 
relationship among inflammation, obesity-related diseases,
and H. pylori infection. Under healthy conditions, the gas-
trointestinal mucosa is in a state of “controlled inflammation”
regulated by a delicate balance of pro- and anti-inflammatory
mediators, examples being shown in Table 2. 
H. pylori and gastric leptin
A selected list of gastro(entero)kines is presented in Table 3, 
ghrelin and leptin being signature examples of these molecules 
(24-30,36-44). The “classical” leptin, an ob gene product, 
is adipocyte-secreted protein/cytokine (31). Leptin, via its 
yin-yang action on specific hypothalamic neurons, exerts an
anorexic effect also associated with acute and chronic inflam-
mation (32-35). Gastric leptin, in tandem with a local pro-in-
flammatory cytokine/chemokine network, may be involved in
local and systemic inflammatory response to H. pylori infec-
tion.  Several studies have indeed found  (positive or negative) 
relations between H. pylori and risk of obesity and related 
diseases. For instance, eradication of H. pylori is associated 
with (i) decreased gastric leptin levels and subsequent weight 
gain (19), and (ii) an increase in both  body mass index and 
cholesterol and triglyceride levels (40). Moreover, H. pylori 
infection is associated with upregulation of adipocyte genes, 
including those encoding for leptin, adiponectin, and resistin; 
an adipocentric insight (6-10,29-35) into H. pylori infection 
is a matter of our ongoing work.
H. pylori and gastric ghrelin
Although several other potent orexigenic peptides, including 
neuropeptide tyrosine (NPY) and agouti-related peptide, have 
been characterized in the brain, ghrelin is the first appetite-
stimulating signal originating from the stomach (reviewed in 
29,30). Ghrelin (“ghre”, meaning grow) is a 28-amino acid 
peptide (3.3 kD) that is synthesized predominantly in mucosal 
endocrine cells called A-like cells, which are located in the 
gastric corpus. Ghrelin was discovered in 1999 (27) and named 
for its ability to stimulate growth hormone (GH) secretion via 
activation of GH secretagogue receptor (5,28-30). However, 
ghrelin is much more that simply a natural GH secretagogue. 
Contrary to leptin, ghrelin has profound orexigenic properties, 
increasing food intake and reducing fat utilization; likewise, 
it exerts many effects similar to those of endocannabinoids, 
known food-intake-stimulating molecules  (30). Altogether, 
leptin-ghrelin tango hypothesis of obesity was proposed (25; 
also 24,26); it may also be danced during H. pylori infection. 
Note that a prolonged period of breastfeeding has been shown 
to reduced the risk of obesity development, whereas gastric 
and plasma ghrelin concentration are maintained at a lower 
level by delayed weaning in rats (28).  
Suzuki et al (5) studied the kinetics of ghrelin in animal 
model of H. pylori infection and found a gradual decrease in 
ghrelin-immunoreactive gastric cells, whereas clinical stud-
ies demonstrated that plasma ghrelin levels may be used as a 
marker for subjects at high risk of atrophic gastritis or gastric 
cancer. This remains to further be pursued in cardiometabolic 
disease (17-23,45,46).
CONCLUSION
Cardiometabolic disease is multifactorial in nature. Here 
we discussed that one important factor that may affect the 
metabolic pathways of glucose and lipids and also food intake 
comprise an altered secretion of gastrokines possibly triggered 
by H. pylori infection. In perspective, a possible involve-
ment of enterokines and adipokines, other essential dancers 
in metabolism, inflammation, and food intake, may also be
studied. Further, a metagenomic (human genome and microbial 
genome/microbiome)  approach (47,48) to metabology of H. 
pylori infection may provide new insights into obesity and 
related cardiometabolic diseases.  
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